Stock VBIV VBI VACCINES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases VBI Vaccines Inc.

Equities

VBIV

CA91822J2020

Delayed Nasdaq
Other stock markets
 20:56:47 29/04/2024 BST 		5-day change 1st Jan Change
0.5413 USD -5.70% Intraday chart for VBI Vaccines Inc. -8.79% -6.38%
04-16 VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
04-15 North American Morning Briefing : Stock Futures -2- DJ

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
VBI Vaccines : 2023 Annual Report
PU
VBI Vaccines Reports Full Year 2023 Financial Results
BU
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BU
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BU
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
BU
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform - VBI Vaccines
AQ
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
BU
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
AQ
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179
AQ
Thinking about buying stock in Arena Group, Dunxin Financial Holdings, Nano-X Imaging, VBI Vaccines, or SuRo Capital?
PR
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
BU
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting
AQ
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
BU
VBI Vaccines Reports Third Quarter 2023 Financial Results
BU
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program - VBI Vaccines
AQ
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
BU
VBI Vaccines Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers against Variants of Concern
AQ
CapitalGainsReport: Nano-Cap Stocks Momentum Watchlist (MGRX, VBIV, GWAV, HIMS)
AQ
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
BU
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM - VBI Vaccines
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VBIV Stock
  4. News VBI Vaccines Inc.
  5. Press Releases